Survival Data
| All patients | ||||||||
| Diagnosis | Diagnosed by… | n | Patients who died (n) | Median follow-up (y) | 2-y survival (%) | 4-y survival (%) | Median survival (y) | Age-adjusted HR |
| LBD | PET | 37 | 9 (24) | 4.79 (4.20–5.38) | 97 | 84 | Not reached [not reached]* | 1 (reference) [1 (reference)]* |
| 1-y follow-up | 34 | 7 (21) | 4.62 (4.13–5.11) | 94 | 85 | Not reached | 1 (reference) | |
| Congruent cases | 31 | 6 (19) | 4.79 (4.08–5.50) | 97 | 87 | Not reached | 1 (reference) | |
| PD | PET | 25 | 4 (16) | 4.58 (4.40–4.76) | 100 | 96 | Not reached [not reached]* | 1 (reference) [1 (reference)]* |
| 1-y follow-up | 23 | 4 (17) | 4.50 (4.11–4.89) | 91 | 91 | Not reached | 1 (reference) | |
| Congruent cases | 18 | 2 (11) | 4.50 (4.05–4.95) | 100 | 100 | Not reached | 1 (reference) | |
| PDD/DLB | PET | 12 | 5 (42) | 5.04 (4.40–5.68) | 92 | 58 | Not reached [not reached]* | 2.01 (0.54–7.56) [1.77 (0.59–5.26)]* |
| 1-y follow-up | 11 | 3 (27) | 5.04 (4.24–5.84) | 100 | 73 | Not reached | 1.05 (0.24–4.69) | |
| Congruent cases | 7 | 3 (43) | 5.27 (4.86–5.68) | 100 | 57 | Not reached | 2.33 (0.39–14.02) | |
| APS | PET | 41 | 25 (61) | 4.56 (4.26–4.86) | 85 | 54 | 4.13 (3.34–4.24) [4.16 (3.26–4.74)]* | 3.81 (1.74–8.30)† [3.39 (1.71–6.71)]*† |
| 1-y follow-up | 44 | 27 (61) | 4.77 (4.46–5.08) | 89 | 55 | 4.13 (3.47–4.29) | 3.85 (1.67–8.87)† | |
| Congruent cases | 38 | 24 (63) | 4.77 (4.37–5.17) | 87 | 53 | 4.05 (3.35–4.25) | 5.19 (2.07–13.03)† | |
| PSP/CBD | PET | 29 | 19 (66) | 4.77 (4.30–5.24) | 86 | 48 | 3.86 (3.19–4.23) [3.86 (2.9–4.68)]* | 5.15 (1.74–15.18)‡ [4.07 (1.71–9.72)]*‡ |
| 1-y follow-up | 31 | 21 (68) | 4.91 (4.54–5.28) | 87 | 48 | 3.86 (3.24–4.23) | 4.46 (1.53–12.99)‡ | |
| Congruent cases | 27 | 19 (70) | 4.91 (4.57–5.25) | 85 | 44 | 3.49 (3.08–4.15) | 7.36 (1.72–31.56)‡ | |
| MSA | PET | 12 | 6 (50) | 4.51 (3.88–5.14) | 83 | 67 | 4.74 (3.05–4.67) [4.74 (3.00–4.74)]* | 5.64 (1.54–20.67)‡ [4.94 (1.57–15.58)]*‡ |
| 1-y follow-up | 13 | 6 (46) | 4.51 (4.10–4.92) | 92 | 69 | 4.74 (3.48–4.84) | 2.80 (0.79–9.88) | |
| Congruent cases | 10 | 5 (50) | 4.51 (4.12–4.90) | 90 | 70 | 4.74 (3.21–4.73) | 6.57 (1.25–34.47)‡ | |
↵* Results from intention-to-treat analyses comprising all 95 patients who gave their consent to participate.
↵† Significant predictor of shorter survival for first-level classification.
↵‡ Significant predictor of shorter survival for second-level classification.
Data in parentheses are percentage or 95% confidence interval. All time specifications refer to time since PET imaging. Two- and 4-y survival rates were estimated by Kaplan–Meier analyses (Fig. 2). Median follow-up was determined by reverse Kaplan–Meier method. Age-adjusted HRs were estimated by Cox proportional hazards analyses including first-level (LBD as reference) and second-level (PD as reference) diagnostic classifications as predictor variables.